Bactiguard (BACTI) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues reached SEK 60.9 million, up 18.9%–19% year-over-year, with net sales up 29.8% to SEK 57.4 million.

• Positive EBITDA of SEK 1.2 million for Q2, marking a turnaround from SEK -55.7 million last year.

• CEO Christine Lind appointed in April; Thomas von Koch reelected as chair in May; Nathaniel Bachrach named interim head of R&D in July.

• Strategic focus on infection prevention technology, expanding partnerships, and a license-focused business model.

• Launch of ZNN Bactiguard trauma implant in Japan and Hydrocyn Aqua wound care product featured at a major European conference.

Financial highlights

• License revenues in Q2 were SEK 37.8 million, with BD contributing SEK 27.6 million and Zimmer Biomet SEK 10.2 million.

• Wound management revenues in Q2 were SEK 14.7 million, up 30.9% year-over-year.

• BIP revenues declined to SEK 4.8 million in Q2 as inventory depletes.

• Total operating expenses in Q2 were SEK 47.8 million, down SEK 33.9 million year-over-year.

• Cash flow from operating activities in Q2 was SEK 16.8 million; cash and equivalents at quarter-end were SEK 105.3 million.

Outlook and guidance

• License revenues are stabilizing, and cost savings from the 2023 transformation are on track to exceed SEK 25 million annually.

• Growth in BD revenues from new markets is expected over time, but limited impact is anticipated in 2024.

• Zimmer Biomet's contributions are expected to increase in future years, with larger volumes likely in 2025 and beyond.

• Long-term growth target: net sales over SEK 1,000 million and EBITDA of SEK 500 million by 2028.

• Continued focus on profitable growth in wound management and expanding R&D capabilities.